Good Therapeutics
Good Therapeutics is a biopharmaceutical organization involved in drug development, with notable activities related to acquiring and advancing therapeutic drug programs.
Facts
- HQ
- Seattle
- Sectors
- Biotechnology, Biopharmaceuticals, Immuno-oncology, Drug development
- Stage
- Series A
- Members see funding amounts. .
Is this your organization? Claim it
Bonum Therapeutics Moves to New Seattle Offices, Plans Team Expansion in Cancer Immunotherapy Push
Seattle biotech startup Bonum Therapeutics is relocating to a new office at 1150 Eastlake Ave E and plans to double its 31-person team as it pursues developing safer immunotherapy cancer drugs. Founded by CEO John Mulligan after a $250 million acquisition of his previous company Good Therapeutics by Roche, Bonum recently raised $93 million to fund its expansion.
Neoleukin Therapeutics Cuts 70% of Workforce, CEO Jonathan Drachman to Step Down Amid Strategic Review
Neoleukin Therapeutics is cutting about 70% of its workforce and exploring strategic alternatives including sale or merger, with CEO Jonathan Drachman stepping down. The company’s stock rose by over 30% following the announcement.
Seattle Biotech Bonum Therapeutics Raises $93M After Roche Acquires Parent Good Therapeutics for $250M
Seattle-based biotech startup Bonum Therapeutics raised $93 million shortly after its parent company Good Therapeutics was acquired by Roche for $250 million. Bonum, led by founder and CEO John Mulligan, uses the same platform technology spun out from Good Therapeutics and aims to develop targeted therapies leveraging continued investor support.
See all 5 stories, episodes and videos about Good Therapeutics.
Seattle Flow is free for everyone.
- Claim and edit your profile
- Get alerts about you, your company, and anything else you care about
- Access the most comprehensive investor list in Seattle
- Join the conversation on news, podcasts, and events